| 发明名称 | Tamper-resistant oral opioid agonist formulations | ||
| 摘要 | Disclosed is a substantially non-releasable form of an opioid antagonist containing the opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic material(s) such that the antagonist is not released or substantially not released during its transit through the gastrointestinal tract when administered orally in an intact oral dosage form. Oral dosage forms containing an opioid agonist and a substantially non-releasable form of an opioid antagonist are also disclosed. | ||
| 申请公布号 | US8936812(B2) | 申请公布日期 | 2015.01.20 |
| 申请号 | US201314045961 | 申请日期 | 2013.10.04 |
| 申请人 | Purdue Pharma L.P. | 发明人 | Oshlack Benjamin;Wright Curtis;Haddox J.David |
| 分类号 | A61K9/14;A61K9/00;A61K9/16;A61K31/485;A61K9/51;A61K9/02;A61K9/20;A61K9/28;A61K9/48;A61K9/50;A61K9/70 | 主分类号 | A61K9/14 |
| 代理机构 | Davidson, Davidson & Kappel, LLC | 代理人 | Davidson, Davidson & Kappel, LLC |
| 主权项 | 1. A substantially non-releasable form of an opioid antagonist comprising: the opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic material(s) such that the opioid antagonist is not released or substantially not released during its transit through the gastrointestinal tract when administered orally in an intact oral dosage form, the intact dosage form comprising an opioid agonist, and less than 1% by weight of the opioid antagonist is released after 36 hours from the intact oral dosage form, the opioid antagonist is separated from the opioid agonist by the one or more pharmaceutically acceptable hydrophobic material(s) in the intact oral dosage form. | ||
| 地址 | Stamford CT US | ||